{
  "id": "6023480b1cb411341a000091",
  "type": "summary",
  "question": "What are the uses of Nirsevimab?",
  "ideal_answer": "A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32759319",
    "http://www.ncbi.nlm.nih.gov/pubmed/32726528"
  ],
  "snippets": [
    {
      "text": "Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: In this trial conducted in both northern and southern hemispheres, we evaluated nirsevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "stly, RSV entry and spread were fully inhibited by neutralizing antibodies palivizumab and the novel nirsevimab. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nfants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants. (Fun",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "c locations and RSV subtypes. Adverse events were similar in the two trial groups, with no notable hypersensitivity reactions.CONCLUSIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726528",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}